Briacell Therapeutics Corp BCTX

$3.04 -0.27 (-8.16%)

Valuation

Market cap
26,546,000
Revenue TTM
$0
Net income TTM
$-26,310,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
130,800
Avg volume
303,800
Day's range
$2.95 – $3.35
Shares out
8,732,000
Stochastic %K
13%
Beta
1.21
Analysts
—
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 921 1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

Merlintrader Nov 1, 2:09 PM
$BCTX closed the week at $3.04 (-11.6% w/w, -8.2% Friday), below the 50-day SMA ($3.77) and below the 200-day ($3.81). RSI14 31.2. Support $2.95, resistance $4.23 (20-day range, bottom). Broad market sell-off on Friday. New hub updated: https://www.merlintrader.com/briacell-therapeutics-stock-hub/
0 replies
superalby Nov 1, 12:07 PM
$BDTX As AI hype settles into valuation realities, and luxury will face downtrend, smart capital is rotating back to Biotech. Driven by Big Pharma’s patent cliff M&As, and historically discounted valuations, the sector is primed for its next major wave. $BDTX 's silevertinib will be the spearhead ! November is here.lets go 🧬📉➡️📈 $BCTX $INO $CABA
1 replies
JediGreen Nov 1, 7:32 AM
$BCTX https://youtu.be/5degIsw-fTI
0 replies
ctrlaltcam Oct 31, 9:24 PM
Adding $IOVA to my bio long calls along $SLS $ONCY $BCTX and $IBRX Hard part is figuring out allocation as I want to full port all of them
0 replies
CoffeeRocks Oct 31, 8:48 PM
$BDTX $INO $PGEN $BCTX $LPCN Pump pump pump OIL Crypto and AI getting a rug pull MonDay BiO WeeK month 🙌🤑👍
0 replies
jfun1 Oct 31, 9:27 AM
$BCTX 26 million mkt cap. Crazy
0 replies
CoffeeRocks Oct 30, 11:08 PM
$INO $BCTX BCTX taking off 🚀
0 replies
diggs24 Oct 30, 9:16 PM
$BCTX Threw another G at it.
1 replies